1. Gonzalez JG, Elizondo G, Saldivar D, et al: Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85: 217, 1988.
2. Miki Y, Asato R, Okumura R, et al: Anterior pituitary gland in pregnancy: hyperintensity at MR. Radiology 187: 229, 1993.
3. Goluboff LG, Ezrin C: Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 29: 1533, 1969.
4. Scheithauer BW, Sano T, Kovacs KT, et al: The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65: 461, 1990.
5. Stefaneanu L, Powell-Braxton L, Won W, Chandrashekar V, Bartke A: Somatotroph and lactotroph changes in the adenohypophyses of mice with disrupted insulin-like growth factor I gene. Endocrinology 140: 3881, 1999.
6. Elster AD, Sanders TG, Vines FS, Chen, MYM. Size and shape of the pituitary gland during pregnancy and postpartum: measurement with MR imaging. Radiology 181: 531, 1991.
7. Dinc H, Esen F, Demirici A, et al. Pituitary dimensions and volume measurements in pregnancy and post partum: MR assessment. Acta Radiol 39: 64, 1998.
8. Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta BioMedica 78(Suppl 1): 255, 2007.
9. Vician L, Shupnik MA, Gorski J: Effects of estrogen on primary ovine pituitary cell cultures: stimulation of prolactin secretion, synthesis, and preprolactin messenger ribonucleic acid activity. Endocrinology 104: 736, 1979.
10. Maurer RA: Relationship between estradiol, ergocryptine, and thyroid hormone: effects on prolactin synthesis and prolactin messenger ribonucleic acid levels. Endocrinology 110: 1515, 1982.
11. Rakoff JS, Yen SSC: Progesterone induced acute release of prolactin in estrogen primed ovariectomized women. J Clin Endocrinol Metab 47: 918, 1978.
12. Maslar IA, Ansbacher R: Effects of progesterone on decidual prolactin production by organ cultures of human endometrium. Endocrinol 118: 2102, 1986.
13. Rigg LA, Lein A, Yen SSC: Pattern on increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 129: 454, 1977.
14. Stern JM, Konner M, Herman TN, Reichlin S. Nursing behavior, prolactin and postpartum amenorrhoea during prolonged lactation in American and !Kung mothers. Clin Endocrinol 25: 247, 1986.
15. Soares MJ, Faria TN, Roby KF, Deb S: Pregnancy and the prolactin family of hormones: Coordination of anterior pituitary, uterine and placental expression. Endocr Rev 12: 402, 1991.
16. Frankenne F, Closset J, Gomez F, et al: The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 66: 1171, 1988.
17. Eriksson L, Frankenne F, Eden S, et al: Growth hormone 24-h serum profiles during pregnancy—lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 106: 949, 1989.
18. Goodman HM, Tai L-R, Ray J, et al: Human growth hormone variant produces insulin-like and lipolytic responses in rat adipose tissue. Endocrinology 129: 1779, 1991.
19. MacLeod JN, Worsley I, Ray J, et al: Human growth hormone-variant is a biologically active somatogen and lactogen. Endocrinology 128: 1298, 1991.
20. Caufriez A, Frankenne F, Enlert Y, et al: Placental growth hormone as a potential regulator of maternal IGF-1 during human pregnancy. Am J Physiol 258: E1014, 1990.
21. Von Werder K, Muller OA, Harth R, et al: Growth hormone releasing factor stimulation test in normal controls. J Endocrinol Invest 7: 185, 1984.
22. Beckers A, Stevenaert A, Foidart J-M, et al: Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71: 725, 1990.
23. Simon P, Decoster C, Brocas H, et al: Absence of human chorionic somatomammotropin during pregnancy associated with two types of gene deletion. Hum Genet 74:235, 1986.
24. Rygaard K, Revol A, Esquivel-Escobedo D, et al: Absence of human placental lactogen and placental growth hormone (HGH-V) during pregnancy: PCR analysis of the deletion. Hum Genet 102:87, 1998.
25. Yoshimura M, Hershman JM: Thyrotropic action of human chorionic gonadotropin. Thyroid 5: 425, 1995.
26. Goodwin TM, Hershman JM: Hyperthyroidism due to inappropriate production of human chorionic gonadotropin. Clin Obstet Gynecol 40: 32, 1997.
27. Pekonen F, Alfthan H, Stenman U-H, Ylikorkala O: Human chorionic gonadotropin (hCG) and thyroid function in early human pregnancy: circadian variation and evidence for intrinsic thyrotropic activity of hCG. J Clin Endocrinol Metab 66: 853, 1988.
28. Glinoer D: The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 18: 404, 1997.
29. Glinoer D, de Nayer P, Bourdoux P, et al: Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 71: 276, 1990.
30. Glinoer D, De Nayer P, Robyn C, Lejeune B, Kinthaert J, Meuris S: Serum levels of intact human chorionic gonadotropin (hCG) and its free α and β subunits, in relation to maternal thyroid stimulation during normal pregnancy. J Endocrinol Invest 16: 881, 1993.
31. Ginsberg J, Lewanczuk RZ, Honore LH: Hyperplacentosis: a novel cause of hyperthyroidism. Thyroid 11: 393, 2001.
32. Gruen JP, Meuris S, De Nayer P, Glinoer D: The thyrotropic role of human chorionic gonadotropin (hCG) in the early stages of twin (vs. single) pregnancy. J Clin Endocrinol 46: 719,1997.
33. Harada K, Hershman JM, Reed AW, et al. Comparison of thyroid stimulators and thyroid hormone concentrations in the sera of pregnant women. J Clin Endocrinol Metab 48: 793, 1979.
34. Jeppsson S, Rannevik G, Liedholm P, et al: Basal and LHRH stimulated secretion of FSH during pregnancy. Am J Obstet Gynecol 127: 32, 1977.
35. Stalla GK, Bost H, Stalla J, et al: Human corticotrophin releasing hormone during pregnancy. Gynecol Endocrinol 3: 1, 1989.
36. Rees LH, Burke CW, Chard T, et al: Possible placental origin of ACTH in normal human pregnancy. Nature 254: 620, 1975.
37. Sasaki A, Shinkawa O, Yoshinaga K. Placental corticotrophin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans. J Clin Invest 84: 1997, 1989.
38. Carr BR, Parker CR Jr, Madden JE, et al: Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 139: 416, 1981.
39. Nolten WE, Lindheimer MD, Rueckert PA, et al: Diurnal patterns and regulation of cortisol secretion in pregnancy. J Clin Endocrinol Metab 51: 466, 1980.
40. Lindsay JR, Nieman LK: The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocrine Reviews 26: 775, 2005
41. Freda PU, Beckers AM, Katznelson L et al. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. In Press.
42. Karaca Z, Tanriverdi F, Unluhizarci K, et al. Pregnancy and pituitary disorders. Eur J Endocrinol 162: 453, 2010.
43. Kredentser JV, Hoskins CF, Scott JZ: Hyperprolactinemia: a significant factor in female infertility. Am J Obstet Gynecol 139: 264, 1981.
44. Molitch ME: Disorders of prolactin secretion. Endocrinol Metab Clin N Amer. 30: 585, 2001.
45. Casanueva FF, Molitch ME, Schlechte JA, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65: 265, 2006.
46. Gillam MP, Molitch MP, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews. 27: 485, 2006.
47. Molitch ME. Prolactinomas and pregnancy. Clin Endocrinol 73: 147, 2010
48. Bigazzi M, Ronga R, Lancranjan I, et al: A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48: 9, 1979.
49. Raymond JP, Goldstein E, Konopka P, et al: Follow-up of children born of bromocriptine-treated mothers. Horm Res 22: 239, 1985.
50. De Mari M, Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy. Mov Disord 17: 428, 2002.
51. Acharya V. Review of pregnancy reports in patients on pergolide treatment. Data on file. Indianapolis (IN): Eli Lilly & Co., 2004.
52. Webster J: A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14: 228, 1996.
53. Stalldecker G, Gil MSG, Guitelman M et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary. In Press.
54. Robert, E., Musatti, L., Piscitelli, G., et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 10, 333, 1996.
55. Divers WA, Yen SSC: Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 62: 425, 1983.
56. Corenblum B, Donovan L: The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59: 671, 1993.
57. Katznelson L, Kleinberg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol 54:183, 2001.
58. Grynberg M, Salenave S, Young J et al. Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 95: 4518, 2010.
59. Kaltsas GA, Androulakis II, Tziveriotis K, et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol 67: 917, 2007.
60. Herman-Bonert V, Seliverstov M, Melmed S: Pregnancy outcome in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83: 727, 1998.
61. Beckers A, Stevenaert A, Foidart J-M, et al: Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71: 725, 1990.
62. Barkan AL, Stred SE, Reno K, et al: Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 69: 1225, 1989.
63. Molitch ME: Clinical manifestations of acromegaly. Endocrine Metab Clin N. Amer. 21:597, 1992.
64. Wilson DM, Bennett A, Adamson GD, et al: Somatomedins in pregnancy: a cross-sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab 55: 858, 1982.
65. Kupersmith MJ, Rosenberg C, Kleinberg D: Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 121: 473, 1994.
66. Okada Y, Morimoto I, Ejima K, et al: A case of active acromegalic woman with a marked increase in serum insulin-like growth factor-1 levels after delivery. Endocr J 44: 117, 1997.
67. Cozzi R, Attanasio R, Barausee M. Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155:279, 2006.
68. Caron P, Broussaud S, Bertherat J, et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95: 000, 2010.
69. Maffei P, Tamagno G, Nardelli GB, et al. Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol 72: 668, 2010.
70. Brian SR, Bidlingmaier M, Wajnrajch MP, et al. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92: 3374, 2007.
71. Caron P, Gerbeau C, Pradayrol L, et al: Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 81: 1164, 1996.
72. Blackhurst G, Strachan MW, Collie D, et al: The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol 56: 401, 2002.
73. Chaiamnuay S, Moster M, Katz MR, Kim YN: Successful management of a pregnant woman with a TSH-secreting pituitary adenoma with surgical and medical therapy. Pituitary 6: 109, 2003.
74. Molitch ME. Nonsecreting tumors and pituitary incidentalomas. Endocrinol Metab Clin N Amer. 37: 151, 2008.
75. Masding MG, Lees PD, Gawne-Cain ML, et al. Visual field compression by a non-secreting pituitary tumor during pregnancy. J R Soc Med 96: 27, 2003.
76. Murata Y, Ando H, Nagasaka T, et al: Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary macroadenoma. J Clin Endocrinol Metab 88: 1988, 2003.
77. Sugita T, Seki K, Nagai Y, et al: Successful pregnancy and delivery after removal of gonadotrope adenoma secreting follicle-stimulating hormone in a 29-year-old amenorrheic woman. Gynecol Obstet Invest 59: 138, 2005.
78. Hall R, Manski-Nankervis J, Goni N, et al. Fertility outcomes in women with hypopituitarism. Clin Endocrinol 65: 71, 2006.
79. Overton CE, Davis CJ, West C, et al. High risk pregnancies in hypopituitary women. Human Reprod 17: 1464, 2002.
80. Esfandiari N, Gotlieb L, Casper RF. Live birth of healthy triplets after in vitro fertilization and embryo transfer in an acromegalic woman with elevated growth hormone. Fertil Steril 83: 1041.e1, 2005.
81. Kübler K, Klingmüller D, Gembruch U, et al. High-risk pregnancy management in women with hypopituitarism. J Perinatol 29: 89, 2009.
82. Mandel SJ, Larsen PR, Seely EW, et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 323: 91, 1990.
83. Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 81: 936, 1972.
84. Kenny FM, Preeyasombat C, Spaulding JS, et al. Cortisol production rate: IV. Infants born of steroid-treated mothers and of diabetic mothers. Infants with trisomy syndrome and with anencephaly. Pediatrics 37: 960, 1966.
85. McKenzie SA, Selley JA, Agnew JE: Secretion of prednisolone into breast milk. Arch Dis Child 50: 894, 1975.
86. Curran AJ, Peacey SR, Shalet SM. Is maternal growth hormone essential for a normal pregnancy? Eur J Endocrinol 139: 54, 1998.
87. Sheehan HL, Davis JC: Pituitary necrosis. Br Med Bull 24: 59, 1968.
88. Kelestimur F: Sheehan’s syndrome. Pituitary 6: 181, 2003.
89. Feinberg E, Molitch M, Endres L, et al. The incidence of Sheehan’s syndrome after obstetric hemorrhage. Fertil Steril 84: 975, 2005.
90. Ozbey N, Inanc S, Aral F, et al: Clinical and laboratory evaluation of 40 patients with Sheehan’s syndrome. Isr J Med Sci 30: 826, 1994.
91. Sheehan HL: The neurohypophysis in post-partum hypopituitarism. J Pathol Bacteriol 85: 145, 1963.
92. Iwasaki Y, Oiso Y, Yamauchi K, et al: Neurohypophyseal function in post-partum hypopituitarism: impaired plasma vasopressin response to osmotic stimuli. J Clin Endocrinol Metab 68: 560, 1989.
93. Bakiri F, Bendib S-E, Maoui R, et al: The sella turcica in Sheehan’s syndrome: computerized tomographic study in 54 patients. J Endocrinol Invest 14: 193, 1991.
94. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocrine Reviews 26: 599, 2005.
95. Rivera J-A. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 9, 35, 2006
96. Molitch ME, Gilliam MP. Lymphocytic Hypophysitis. Horm Res 68(S5): 145, 2007.
97. Nishiki M, Murakami Y, Ozawa Y, Kato Y: Serum antibodies to human pituitary membrane antigens in patients with autoimmune lymphocytic hypophysitis and infundibuloneurohypophysitis. Clin Endocrinol 54: 327, 2001.
98. Leiba S, Schindel B, Weinstein R, et al: Spontaneous postpartum regression of pituitary mass with return of function. JAMA 255: 230, 1986.
99. McGrail KM, Beyerl BD, Black PM, et al: Lymphocytic adenohypophysitis of pregnancy with complete recovery. Neurosurgery 20: 791, 1987.
100. Lindheimer MD, Davison JM: Osmoregulation, the secretion of arginine vasopressin and its metabolism during pregnancy. Eur J Endocrinol 132: 133, 1995.
101. Davison JM, Shiells EA, Barron WM, et al: Changes in the metabolic clearance of vasopressin and of plasma vasopressinase throughout human pregnancy. J Clin Invest 83: 1313, 1989.
102. Barron WM: Water metabolism and vasopressin secretion during pregnancy. Baillieres Clin Obstet Gynaecol 1: 853, 1987.
103. Durr JA: Diabetes insipidus in pregnancy. Am J Kidney Dis 9: 276, 1987.
104. Huchon DJR, Van Zijl JAWM, Campbell-Brown MB, et al: Desmopressin as a test of urinary concentrating ability in pregnancy. J Obstet Gynecol 2: 206, 1982.
105. Russell JA, Leng G, Douglas AJ: The magnocellular oxytocin system, the fount of maternity: adaptations in pregnancy. Frontiers in Neuroendocrinol 24: 27, 2003.
106. Gibbens GLD, Chard T: Observations on maternal oxytocin release during human labor. Am J Obstet Gynecol 126: 243, 1976.
107. Dawood MY, Khan-Dawood FS, Wahi R, et al: Oxytocin release and plasma anterior pituitary and gonadal hormones in women during lactation. J Clin Endocrinol Metab 52: 678, 1981.
108. Soule SG, Monson JP, Jacobs HS: Transient diabetes insipidus in pregnancy—a consequence of enhanced placental clearance of arginine vasopressin. Hum Reprod 10: 3322, 1995.
109. Yamamoto T, Ishii T, Yoshioka K, et al: Transient central diabetes insipidus in pregnancy with a peculiar change in signal intensity on T1-weighted magnetic resonance images. Intern Med 42: 513, 2003.
110. Kaellen BAJ, Carlsson SS, Bengtsson BKA: Diabetes insipidus and use of desmopressin (Minirin) during pregnancy. Eur J Endocrinol 132: 144-6, 1995.
111. Ray JG: DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecolol Survey 53: 450, 1998.
112. El-Hennawy AS, Bassi T, Koradia N, Bocirnea A: Transient gestational diabetes insipidus: report of two cases and review of pathophysiology and treatment. J Mat-Fet Neonat Med 14: 349, 2003.
113. Kennedy S, Hall PM, Seymour AE, Hague WM: Transient diabetes insipidus and acute fatty liver of pregnancy. Br J Obstet Gynaecol 101: 387, 1994.
114. Krege J, Katz VL, Bowes Jr WA: Transient diabetes insipidus of pregnancy. Obstet Gynecolol Survey 44: 789, 1989.
115. Ellidokuz E, Uslan I, Demir S, Cevrioglu S, Tufan G: Transient postpartum diabetes insipidus associated with HELLP syndrome. J Obstet Gynaecol Res 32: 602, 2006.
116. Raziel A, Rosenberg T, Schreyer P, et al: Transient postpartum diabetes insipidus. Am J Obstet Gynecol 164: 616, 1991.
117. Hawker RW, North WG, Colbert IC, Lang LP: Oxytocin blood levels in two cases of diabetes insipidus. Br J Obstet Gynaecol 74: 430, 1987.
118. McLean M, Smith R: Corticotropin-releasing hormone in human pregnancy and parturition. Trends in Endocrinol Metab 10: 174, 1999.
119. Goland RS, Wardlaw SL, Stark RE, et al: High levels of corticotropin-releasing hormone immunoactivity in maternal and fetal plasma during pregnancy. J Clin Endocrinol Metab 63: 1199, 1986.
120. Demey-Ponsart E, Foidart JM, Sulon J, et al: Serum CBG, free and total cortisol and circadian patterns of adrenal function in normal pregnancy. J Steroid Biochem 16: 165, 1982.
121. Dorr HG, Heller A, Versmold HT, et al: Longitudinal study of progestins, mineralocorticoids, and glucocorticoids throughout human pregnancy. J Clin Endocrinol Metab 68: 863, 1989.
122. Rosenthal HE, Slaunwhite WR, Sandberg AA: Transcortin, a corticosteroid-binding protein of plasma: Cortisol and progesterone interplay and unbound levels of these steroids in pregnancy. J Clin Endocrinol Metab 29: 352, 1969.
123. Brown MA, Wang J, Whitworth JA: The renin-angiotensin-aldosterone system in preeclampsia. Clin Exp Hypertens 19: 713, 1997.
124. Wilson M, Morganti AA, Zervoudakis I, et al: Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. Am J Med 8: 97, 1980.
125. Boonshaft B, O’Connell JM, Hayes JM, et al: Serum renin activity during normal pregnancy: effect of alterations of posture and sodium intake. J Clin Endocrinol Metab 28: 1641, 1968.
126. Jones KM, Lloyd-Jones R, Riondel A, et al: Aldosterone secretion and metabolism in normal men and women and in pregnancy. Acta Endocrinol 30: 321, 1959.
127. Ehrlich EN, Lindheimer MD: Effect of administered mineralocorticoids or ACTH in pregnant women. Attenuation of kaliuretic influence of mineralocorticoids during pregnancy. J Clin Invest 51: 1301, 1972.
128. Biglieri EG, Slaton, Jr, PE: Pregnancy and primary aldosteronism. J Clin Endocrinol Metab 27: 1628, 1967.
129. Bevan JS, Gough MH, Gillmer MDG, et al. Cushings syndrome in pregnancy. The timing of definitive treatment. Clin Endocrinol 27: 225, 1987.
130. Casson IF, Davis JC, Jeffreys RV, et al. Successful management of Cushings disease during pregnancy by transsphenoidal adenectomy. Clin Endocrinol 27: 423, 1987.
131. Aron DC, Schnall AM, Sheeler LR. Cushings syndrome and pregnancy. Am J Obstet Gynecol 162: 244, 1990.
132. Buescher MA, McClamrock HD, Adashi EY. Cushings syndrome in pregnancy. Obstet Gynecol 79: 130, 1992.
133. Ross RJ, Chew SL, Perry L, et al. Diagnosis and selective cure of Cushing’s disease during pregnancy by transsphenoidal surgery. Eur J Endocrinol 132: 722, 1995.
134. Chico A, Manzanares JM, Halperin I, et al. Cushing’s disease and pregnancy. Eur J Obstet Gynecol Reprod Biol 64: 143, 1996.
135. Guilhaume B, Sanson ML, Billaud L, et al. Cushing’s syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Eur J Med 1: 83, 1992.
136. Wallace C, Toth EL, Lewanczuk RZ, Siminoski K: Pregnancy-induced Cushing's syndrome in multiple pregnancies. J Clin Endocrinol Metab 81: 15, 1996.
137. Kasperlik-Zaluska AA, Szczupacka I, Leszczynska-Bystrzanowska J, et al. Pregnancy-dependent Cushing's syndrome in three pregnancies. Br J Obstet Gynaecol 107: 810, 2000.
138. Pinette MG, Pan YQ, Oppenheim D, et al. Bilateral inferior petrosal sinus corticotropin sampling with corticotropin-releasing hormone stimulation in a pregnant patient with Cushing’s syndrome. Am J Obstet Gynecol 171: 563, 1994.
139. Kreines K, DeVaux WD. Neonatal adrenal insufficiency associated with maternal Cushings syndrome. Pediatrics 47: 516, 1971.
140. Amado JA, Pesquera C, Gonzalez EM, et al: Successful treatment with ketoconazole of Cushing’s syndrome in pregnancy. Postgrad Med J 66: 221, 1990.
141. Berwaerts J, Verhelst J, Mahler C, et al. Cushing’s syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 13: 175, 1999.
142. Mellor A, Harvey RD, Pobereskin LH, et al. Cushing’s disease treated by trans-sphenoidal selective adenomectomy in mid-pregnancy. Br J Anaesth 80: 850, 1998.
143. Madhun ZT, Aron DC: Cushing’s disease in pregnancy. In: Bronstein MD, editor. Pituitary tumors and pregnancy. Norwell (MA): Kluwer Academic Publishers, p. 149-172, 2001.
144. Hana V, Dokoupilova M, Marek J, et al. Recurrent ACTH-independent Cushing’s syndrome in multiple pregnancies and its treatment with metyrapone. Clin Endocrinol 54: 277, 2001.
145. Lindsay JR, Jonklaas J, Oldfield EH, et al. Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90: 3077, 2005.
146. Vilar L, Freitas MDC, Lima LHC, et al. Cushing’s syndrome in pregnancy. An overview. Arq Bras Endocrinol Metab 51:1293, 2007.
147. Chui MH, Őzbey NC, Ezzat S, et al. Case report: Adrenal LH/hCG receptor overexpression and gene amplification causing pregnancy-induced Cushing’s syndrome. Endocr Pathol 20:256, 2009.
148. Tajika T, Shinozaki T, Watanabe H, et al. Case report of a Cushing’s syndrome patient with multiple pathologic fractures during pregnancy. J Orthop Sci 7: 498, 2002.
149. Putignano P, Toja P, Dubini A, et al: Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 88: 4153, 2003.
150. Magiakou MA, Mastorakos G, Rabin D, et al: The maternal hypothalamic-pituitary-adrenal axis in the third trimester of human pregnancy. Clin Endocrinol 44: 419, 1996.
151. Connell JM, Cordiner J, Davies DL, et al: Pregnancy complicated by Cushing’s syndrome: potential hazard of metyrapone therapy: case report. Br J Obstet Gynaecol 92: 1192, 1985.
152. Close CF, Mann MC, Watts JF, et al: ACTH-independent Cushing’s syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol 39: 375, 1993.
153. Gormley MJ, Hadden DR, Kennedy TL, et al: Cushing’s syndrome in pregnancy—treatment with metyrapone. Clin Endocrinol 16: 283, 1982.
154. Cohen-Kerem R, Railton C, Orfen D, et al. Pregnancy outcome following non-obstetric surgical intervention. Am J Surgery 190:467;2005
155. Albert E, Dalaker K, Jorde R, et al. Addison’s disease and pregnancy. Acta Obstet Gynecol Scand 68:185, 1989.
156. Erichsen MM, Husebye ES, Michelsen TM et al. Sexuality and fertility in women with Addison’s disease. J Clin Endocrinol Metab 95; 4354, 2010.
157. Drucker D, Shumak S, Angel A. Schmidt’s syndrome presenting with intrauterine growth retardation and postpartum Addisonian crisis. Am J Obstet Gynecol 149: 229, 1984.
158. Gamlen TR, Aynsley-Green A, Irvine WJ, et al. Immunological studies in the neonate of a mother with Addison’s disease and diabetes mellitus. Clin Exp Immunol 28: 192, 1977.
159. Osler M: Addison’s disease and pregnancy. Acta Endocrinol 41: 67, 1962.
160. O’Shaughnessy RW, Hackett KJ: Maternal Addison’s disease and fetal growth retardation: a case report. J Reprod Med 29: 752, 1984.
161. Grottolo A, Ferrari V, Mariano M, et al: Primary adrenal insufficiency, circulating lupus anticoagulant and anticardiolipin antibodies in a patient with multiple abortions and recurrent thrombotic episodes. Haematologica 73: 517, 1988.
162. Björnsdottir S, Cnattingius S, Brandt L et al. Addison’s disease in women is a risk factor for an adverse pregnancy outcome. J Clin Endocrinol Metab. Doi:10.1210/jc.2010-0108.
163. Gradden C, Lawrence D, Doyle PM, et al: Uses of error: Addison’s disease in pregnancy. Lancet 357: 1197, 2001.
164. Otta CF, de Meresian PS, Iraci GS, et al.. Pregnancies associated with primary adrenal insufficiency. Fertil Steril 90:1199e17, 2008.
165. McKenna DS, Wittber GM, Nagaraja HN, et al: The effects of repeat doses of antenatal corticosteroids on maternal adrenal function. Am J Obstet Gynecol 183: 669, 2000.
166. Grinspoon SK, Biller BM. Clinical review 62: laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 79: 79: 923, 1994.
167. Nolten WE, Lindheimer MD, Oparil S, et al: Desoxycorticosterone in normal pregnancy: I. sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol. Am J Obstet Gynecol 132: 414, 1978.
168. Schulte HM, Weisner D, Allolio B: The corticotrophin releasing hormone test in late pregnancy: lack of adrenocortiocotrophin and cortisol response. Clin Endocrinol 33: 99, 1990.
169. Nigam R, Bhatia E, Miao D, et al: Prevalence of adrenal antibodies in Addison’s disease among north Indian Caucasians. Clin Endocrinol 59: 593, 2003.
170. Symonds EM, Craven DJ: Plasma renin and aldosterone in pregnancy complicated by adrenal insufficiency. Br J Obstet Gynaecol 84: 191, 1977.
171. Seaward PG, Guidozzi F, Sonnendecker EW: Addisonian crisis in pregnancy: case report. Br J Obstet Gynaecol 96: 1348, 1989.
172. Ambrosi B, Barbetta L, Morricone L: Diagnosis and management of Addison’s disease during pregnancy. J Endocrinol Invest 26: 698, 2003.
173. Normington EM, Davies D: Hypertension and oedema complicating pregnancy in Addison’s disease. BMJ 1: 148, 1972.
174. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326: 226, 1992.
175. Kream J, Mulay S, Fukushima DK, et al: Determination of plasma dexamethasone in the mother and the newborn after administration of the hormone in a clinical trial. J Clin Endocrinol Metab 56: 127, 1983.
176. Kenny FM, Preeyasombat C, Spaulding JS, et al. Cortisol production rate. IV. Infants born of steroid-treated mothers and of diabetic mothers. Infants with trisomy syndrome and with anencephaly. Pediatrics 37: 960, 1966.
177. Sidhu RK, Hawkins DR: Prescribing in pregnancy: corticosteroids. Clin Obstet Gynaecol 8: 383, 1981.
178. Speiser PW, Azziz R, Baskin LS,et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 95: 4133, 2010.
179. Garner PR: Congenital adrenal hyperplasia in pregnancy. Sem Perinatol 22:446, 1998.
180. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21: 245, 2000.
181. Forest MG: Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 10: 469, 2004.
182. New MI, Carlson A, Obeid J, et al: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 86: 5651, 2001.
183. Premawardhana LDKE, Hughes IA, Read GF, Scanlon MF: Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol 46: 327, 1997.
184. Feldman S, Billaud L, Thalabard J-C, et al: Fertility in women with late onset adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 74: 635, 1992.
185. Klingensmith GJ, Garcia SC, Jones HW, et al: Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effect of height, sexual maturity, and fertility. J Pediatr 90: 996, 1977.
186. Krone N, Wachter I, Stafanidou M, et al. Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood. Clin Endocrinol 55: 523, 2001.
187. New MI, Lorenzen F, Lerner AJ, et al: Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57: 320, 1983.
188. Azziz R, DeWailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 78: 810, 1994.
189. Coleman MA, Honour JW: Reduced maternal dexamethasone dosage for the prenatal treatment of congenital adrenal hyperplasia. Brit J Obstet Gynecol 111: 176, 2004.
190. Pang S, Pollack MS, Marshall RN, Immken LD. Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 322: 111, 1990.
191. Pang S, Clark AT, Freeman LC, et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 75: 249, 1992.
192. Baron F, Sprauve ME, Huddleston JF, Fisher AJ: Diagnosis and surgical treatment of primary aldosteronism in pregnancy: a case report. Obstet Gynecol 86: 644, 1995.
193. Solomon CG, Thiet M-P, Moore F Jr, Seely EW: Primary hyperaldosteronism in pregnancy. A case report. J Reprod Med 41: 255, 1996.
194. Webb JC, Bayliss P: Pregnancy complicated by primary hyperaldosteronism. Southern Med J 90: 243, 1997.
195. Robar CA, Poremba JA, Pelton JJ, et al. Current diagnosis and management of aldosterone-producing adenomas during pregnancy. The Endocrinologist 8: 403, 1998.
196. Okawa T, Asano K, Hashimoto T, et al: Diagnosis and management of primary aldosteronism in pregnancy: case report and review of the literature. Am J Perinatol 19: 31, 2002.
197. Nursal TZ, Caliskan K, Ertorer E, Parlakgumus A, Moray G. Laparoscoptic treatment of primary hyperaldosteronism in a pregnant patient. J Can Chir 52;E188, 2009
198. Escher G. Hyperaldosteronism in pregnancy. Ther Adv Cardiovasc Dis 3: 123, 2009.
199. Wyckoff JA, Seely EW, Hurwitz S, et al: Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension 35: 668, 2000.
200. Fujiyama S, Mori Y, Matsubara H, et al: Primary aldosteronism with aldosterone-producing adrenal adenoma in a pregnant woman. Intern Med 38: 36, 1999.
201. Neerhof MG, Shlossman PA, Poll DS, et al: Idiopathic aldosteronism in pregnancy. Obstet Gynecol 78: 489, 1991.
202. Matsumoto J, Miyake H, Isozaki T, et al: Primary aldosteronism in pregnancy. J Nippon Med Sch 67: 275, 2000.
203. Deruelle P, Dufour P, Magnenant E, et al: Maternal Bartter’s syndrome in pregnancy treated by amiloride. Eur J Obstet Gynecol Reprod Biol 115: 106, 2004.
204. Nezo M, Miura Y, Noshiro T, Inoue M: Primary aldosteronism as a cause of severe postpartum hypertension in two women. Am J Obstet Gynecol 182: 745, 2000.
205. Murakami T, Ogura EW, Tanaka Y, Yamamoto M: High blood pressure lowered by pregnancy. Lancet 356: 1980, 2000.
206. Freier DT, Thompson NW: Pheochromocytoma and pregnancy: The epitome of high risk. Surgery 114: 1148, 1993.
207. Oliva R, Angelos P, Kaplan E, et al. Pheochromocytoma in pregnancy. A case series and review. Hypertension 55: 600, 2010.
208. Sarathi V, Lila AR, Bandgar TR, et al. Pheochromocytoma and pregnancy: a rare but dangerous combination. Endocr Pract 16: 300, 2010.
209. Botchan A, Hauser R, Kupfermine M, et al: Pheochromocytoma in pregnancy: case report and review of the literature. Obstet Gynecol Surv 50: 321, 1995.
210. Levin N, McTighe A, Abdel-Aziz MIE. Extra-adrenal pheochromocytoma in pregnancy. Maryland State Med J 32: 377, 1983.
211. Oishi S, Sato T: Pheochromocytoma in pregnancy: a review of the Japanese literature. Endocrine J 41: 219, 1994.
212. Lau P, Permezel M, Dawson P, et al. Phaeochromocytoma in pregnancy. Aust N Z J Obstet Gynaecol 36: 472, 1996.
213. Saarikoski S: Fate of noradrenaline in the human fetoplacental unit. Acta Physiol Scand 421 (Suppl): 1, 1974.
214. Dahia PLM, Hayashida CY, Strunz C, Abelin N, Toledo SPA: Low cord blood levels of catecholamine from a newborn of a pheochromocytoma patient. Eur J Endocrinol 130: 217, 1994.
215. Barzel US, Barlian Z, Runmery G, et al: Pheochromocytoma and pregnancy. Am J Obstet Gynecol 89: 519, 1964.
216. Bakri YN, Ingemansson SE, Ali A, Parikh S: Pheochromocytoma and pregnancy: Report of three cases. Acta Obstet Gynecol Scand 71: 301, 1992.
217. Harper MA, Murnaghan GA, Kennedy L, Hadden DR, Atkinson AB: Phaeochromocytoma in pregnancy: Five cases and a review of the literature. Br J Obstet Gynaecol 96: 594, 1989.
218. Combs CA, Easterling TR, Schmucker BC: Hemodynamic observations during paroxysmal hypertension in a pregnancy with pheochromocytoma. Obstet Gynecol 74: 439, 1989.
219. Falterman CJ, Kreisberg R: Pheochromocytoma: Clinical diagnosis and management. South Med J 75: 321, 1982.
220. Kalff V, Shapiro B, Lloyd R, et al: The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Intern Med 142: 2092, 1982.
221. Kothari A, Bethune M, Manwaring J, Astley N, Wallace E: Massive bilateral phaeochromocytomas in association with von Hippel Lindau syndrome in pregnancy. Aust NZ J Obstet Gynaecol 39: 381, 1999.
222. Kolomeyevskaya N, Blazo M, van den Veyver I, et al. Pheochromocytoma and von Hippel-Lindau in pregnancy. Am J Perinatol 22:257, 2010.
223. Freier DT, Eckhauser FE, Harrison TS: Pheochromocytoma. Arch Surg 115: 388, 1980.
224. Sheps SG, Jiang NS, Klee GC: Diagnostic evaluation of pheochromocytoma. Endocrinol Metab Clin North Am 17: 397, 1988.
225. Pederson EB, Rasmussen AB, Christensen NJ, et al: Plasma noradrenaline and adrenaline in pre-eclampsia, essential hypertension in pregnancy and normotensive pregnant control subjects. Acta Endocrinol (Copenh) 99: 594, 1982.
226. Moodley J, McFadyen ML, Dilraj A, et al. Plasma noradrenaline and adrenaline levels in eclampsia. S Afr Med J 80: 191, 1991.
227. Santeiro ML, Stromquist C, Wyble L: Phenoxybenzamine placental transfer during the third trimester. Ann Pharmacother 30: 1249, 1996.
228. Lyons CW, Colmorgen GHC: Medical management of pheochromocytoma in pregnancy. Obstet Gynecol 72: 450, 1988.
229. Ahlawat SK, Jain S, Kumari S, et al, Pheochromocytoma associated with pregnancy: Case report and review of the literature. Obstet Gynecol Surv 54: 728, 1999.
230. Devoe LD, O’Dell BE, Castillo RA, et al. Metastatic pheochromocytoma in pregnancy and fetal biophysical assessment after maternal administration of alpha-adrenergic, beta-adrenergic, and dopamine antagonists. Obstet Gynecol 68 (Suppl 3): 15S, 1986.
231. Chatterjee TK, Parekh U: Phaeochromocytoma in pregnancy. Aust NZ J Obstet Gynaecol 25: 290, 1985.
232. Finkenstedt G, Gasser RW, Hofle G, et al: Pheochromocytoma and sub-clinical Cushing’s syndrome during pregnancy: Diagnosis, medical pre-treatment and cure by laparoscopic unilateral adrenalectomy. J Endocrinol Invest 22: 551, 1999.
233. Schenker JG, Granat M: Phaeochromocytoma and pregnancy—An updated appraisal. Aust NZ J Obstet Gynaecol 22: 1, 1982.
234. Schenker JG, Chowers I: Pheochromocytoma and pregnancy: Review of 89 cases. Obstet Gynecol Surv 26: 739, 1971.